SCHEMBL25399737

SCHEMBL25399737

COC(=O)c1ccc2cn(Cc3cccc(OC)c3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD74 P04233 2/20 0.48
MIF P14174 2/20 0.48
HCAR3 P49019 1/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.46
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 1/20 0.45
PKM P14618 1/20 0.45
ABHD6 Q9BV23 1/20 0.45
MAPT P10636 1/20 0.45
PTGER4 P35408 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
DRD4 P21917 1/20 0.45
AADAT Q8N5Z0 1/20 0.45
LMNA P02545 1/20 0.45
P2RY14 Q15391 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25402742 0.90 FAAH (0.50) CD74MIFHCAR3KMT2AHDAC1
SCHEMBL30585019 0.90 HCAR3 (0.60) CD74MIFHCAR3KMT2AMEN1
SCHEMBL25401150 0.90 HCAR3 (0.60) CD74MIFHCAR3KMT2AMEN1
SCHEMBL25403656 0.90 KDM4E (0.42) CD74MIFHDAC1ABHD6ADORA3
SCHEMBL30584923 0.89 HDAC1 (0.54) HCAR3KMT2AMEN1HDAC1HDAC7
SCHEMBL25401828 0.89 CYSLTR1 (0.49) CD74MIFKMT2AMEN1LMNA
SCHEMBL12706998 0.87 CA1 (0.47) KMT2AMEN1HDAC1HDAC7ADORA3
SCHEMBL5767415 0.87 P2RX7 (0.48) CD74MIFKMT2AMEN1MAPT
SCHEMBL25401651 0.87 THRB (0.53) CD74MIFABHD6MAPTLMNA
SCHEMBL25403016 0.87 MRGPRX4 (0.46) CD74MIFKMT2AMEN1ABHD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197369-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2025-06-19 US disclosed
EP-4494640-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sookmyung Women's University Industry-Academic Cooperation Foundation (KR) 2025-01-22 EP disclosed
CN-119212701-A Novel histone deacetylase heterocycle inhibitor and pharmaceutical composition containing the same 淑明女子大学校 产学协力团 2024-12-27 CN disclosed
WO-2023177250-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 숙명여자대학교산학협력단 2023-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197369-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HDAC1, HDAC6, HDAC5 CD74 1335/4885MIF 1856/4885HCAR3 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.